ABIO | ARCA biopharma, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.2469 - 28.80
52 Week Range	2.2469 - 53.88
Beta	0.74
Implied Volatility	540.19%
IV Rank	114.32%
Day's Volume	290,850
Average Volume	13,857
Shares Outstanding	1,208,930
Market Cap	34,817,184
Sector	Healthcare
Industry	Biotechnology
IPO Date	1997-08-08

Valuation
Profitability
Growth
Health
P/E Ratio	-4.90
Forward P/E Ratio	N/A
EPS	-5.88
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	3
Country	USA
Website	ABIO

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.

ABIO's peers: ATHE, IMRN, KZIA, NNVC, RNXT, VRPX

*Chart delayed

Analyzing fundamentals for ABIO we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see ABIO Fundamentals page.

Watching at ABIO technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on ABIO Technicals page.